EAN 2023 | How do the approved NMOSD therapies work?

Bruce Cree, MD, PhD, MAS, University of California San Francisco, San Francisco, CA, explores the game-changing treatments recently introduced for patients with neuromyelitis optica spectrum disorder (NMOSD). The three approved therapies – eculizumab, inebilizumab, and satralizumab- target different aspects of NMOSD immunopathogenesis. This marks a remarkable shift from having no proven therapies to highly effective options, revolutionizing NMOSD management. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.